Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care

2021 ◽  
Author(s):  
M. L. Morieri ◽  
◽  
N. Vitturi ◽  
A. Avogaro ◽  
G. Targher ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Hepatic Steatosis ◽  
Specialist Care ◽  
Glucose Lowering

Angelica gigas Ameliorates Hyperglycemia and Hepatic Steatosis in C57BL/KsJ-db/db Mice via Activation of AMP-Activated Protein Kinase Signaling Pathway

2016 ◽  
Vol 44 (08) ◽  
pp. 1627-1638 ◽  
Author(s):  
Ui-Jin Bae ◽  
Eun-Kyung Choi ◽  
Mi-Ra Oh ◽  
Su-Jin Jung ◽  
Joon Park ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Protein Kinase ◽  
Hepatic Steatosis ◽  
Oral Glucose ◽  
Model Assessment ◽  
Angelica Gigas ◽  
Glucose Lowering ◽  
Angelica Gigas Nakai ◽  
Amp Activated Protein Kinase

The prevention and management of type 2 diabetes mellitus has become a major global public health challenge. Decursin, an active compound of Angelica gigas Nakai roots, was recently reported to have a glucose-lowering activity. However, the antidiabetic effect of Angelica gigas Nakai extract (AGNE) has not yet been investigated. We evaluated the effects of AGNE on glucose homeostasis in type 2 diabetic mice and investigated the underlying mechanism by which AGNE acts. Male C57BL/KsJ-db/db mice were treated with either AGNE (10 mg/kg, 20 mg/kg, and 40 mg/kg) or metformin (100 mg/kg) for 8 weeks. AGNE supplementation (20 and 40 mg/kg) significantly decreased fasting glucose and insulin levels, decreased the areas under the curve of glucose in oral glucose tolerance and insulin tolerance tests, and improved homeostatic model assessment-insulin resistant (HOMA-IR) scores. AGNE also ameliorated hepatic steatosis, hyperlipidemia, and hypercholesterolemia. Mechanistic studies suggested that the glucose-lowering effect of AGNE was mediated by the activation of AMP activated protein kinase, Akt, and glycogen synthase kinase-3[Formula: see text]. AGNE can potentially improve hyperglycemia and hepatic steatosis in patients with type 2 diabetes.

Impact of Glucose-Lowering Drugs on Mortality and Other Adverse Outcomes in Patients with Type 2 Diabetes Admitted for COVID-19

2020 ◽  
Author(s):  
Luis Miguel Pérez-Belmonte ◽  
José David Torres-Peña ◽  
María D. López-Carmona ◽  
M. Mar Ayala-Gutiérrez ◽  
Francisco Fuentes-Jiménez ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adverse Outcomes ◽  
Glucose Lowering

scholarly journals Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

2021 ◽  
Author(s):  
Rick I. Meijer ◽  
Trynke Hoekstra ◽  
Niels C. Gritters van den Oever ◽  
Suat Simsek ◽  
Joop P. van den Bergh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Hospital Admission ◽  
Clinical Outcomes ◽  
Primary Outcome ◽  
Infectious Complications ◽  
Glucose Lowering ◽  
Diabetes Severity ◽  
Outcome Mortality

Abstract Purpose Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. Methods We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users. Results No differences were found in the primary outcome mortality (matched-analysis = odds-ratio: 0,94 [95% confidence interval: 0,69 – 1,28], p-value: 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1: users of metformin and sulphonylurea; subgroup 2: users of any insulin combination), allowing to correct for diabetes severity, did not yield different results. Conclusions We conclude that outpatient use of a DPP-4 inhibitor does not affect the clinical outcomes of patients with type 2 diabetes who are hospitalized because of COVID-19 infection.

RISK-1: One-year Retrospective Study to Assess Cardiovascular Risk at the Onset of Type 2 Diabetes Mellitus in Slovenia

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154481
Author(s):  
Iris Marolt ◽  
Jana Komel ◽  
Elena Kuzmina ◽  
Anja Babič ◽  
Renata Kopriva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Retrospective Study ◽  
One Year

scholarly journals The Relationship Between Glucose-Lowering Medications, Adherence, and Outcomes in Patients with Type 2 Diabetes

2015 ◽  
Vol 18 (7) ◽  
pp. A343 ◽  
Author(s):  
J Piercy ◽  
G Milligan ◽  
MJ Davies ◽  
B Detournay ◽  
D Orozco Beltran ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Lowering ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document